Chi G, et al. - In this bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trials, researchers compared the safety and efficacy of four antithrombotic regimens with vitamin K antagonist (VKA)-based triple therapy in stented atrial fibrillation (AF) patients. The regimens used were: rivaroxaban (riva) 15 mg daily + P2Y₁₂ inhibitor; riva 2.5 mg twice daily + P2Y₁₂ inhibitor + aspirin; dabigatran (dabi) 110 mg twice daily + P2Y₁₂ inhibitor; and dabi 150 mg twice daily + P2Y₁₂ inhibitor. They found that, compared with VKA plus dual antiplatelet therapy, more favorable outcomes were achieved with rivaroxaban- and dabigatran-based regimens among patients with AF undergoing percutaneous coronary intervention.